Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRE-4.5: FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab in first-line BRAF-mutated metastatic colorectal cancer
2015-004849-11Phase 2Completed
- Sponsor
- LMU Klinikum
- Start
- Jul 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab, bevacizumab, irinotecan, fluorouracil, folinic acid and 1 more in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by LMU Klinikum. Primary endpoint: Objective response rate. Started Jul 2016; status: completed.
02
Drugs
cetuximabbevacizumabirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2015-004849-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004849-11.